Valneva's chikungunya vaccine suspended in the United States after new adverse reactions

The Franco-Austrian Valneva vaccine against Chikungunya has been suspended in the United States following new cases of side effects.

US health authorities have suspended approval of the anti-chikungunya vaccine developed by the Franco-Austrian laboratory Valneva, basing their decision on new cases of side effects, the group announced on Monday, August 25.

"This suspension is effective immediately and involves a halt to the shipment and sale of Ixchiq," the vaccine's brand name, "in the United States," Valneva said in a statement, after the treatment was suspended in the spring for older people in the European Union before being reauthorized.

>> More information to come on BFMTV.com...